How GHK-Cu signals the body to rebuild collagen — and what the research actually shows

GHK-Cu (copper peptide) is among the best-studied peptides in the skin-remodeling space. Unlike many compounds that are nascent in human trials, GHK-Cu has been investigated since the 1970s, with a growing body of in vitro, animal, and human evidence supporting its role in collagen synthesis, wound healing, and dermal rejuvenation.

How the mechanism works

GHK-Cu functions primarily by activating transcription factors that upregulate collagen I and III production in dermal fibroblasts. It also promotes the synthesis of fibronectin and glycosaminoglycans — two structural proteins that give skin its elasticity and hydration. At the cellular level, it acts as a signaling molecule that tells aging fibroblasts to behave more like younger ones.

Evidence tier: B

We classify GHK-Cu as Tier B — emerging human data with a solid mechanistic basis. Multiple small human trials have demonstrated measurable increases in skin density and collagen content. Larger randomized controlled trials remain limited, which is why we stop short of Tier A.

What patients typically report

Most patients in our Aurora Renewal protocol begin noticing changes in skin texture and luminosity between weeks 4 and 6. By week 12, physician-observed improvements in skin density are common. The compound is well-tolerated subcutaneously or topically and has no known significant adverse effects at standard dosing.